All sponsors

Novo Nordisk A/S $NVO

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS61
PHASE 3 / 2-350
RECRUITING27
READOUTS ≤12 MONTHS15
READOUT SLIPPED >6 MO36%

Delay Index: of 28 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +2.5 months). See all sponsors →

Open Novo Nordisk A/S on the live radar map → 📅 $NVO readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Somapacitan
NCT03878446
P2Active, not recruitingShort Stature Children Born Small for Gestational Age (SGA)622021-05-05 (+21 mo)
explorer7
NCT04083781
P3Active, not recruitingHaemophilia A With Inhibitors; Haemophilia B With Inhibitors1342021-12-27 (+14 mo)
explorer8
NCT04082429
P3Active, not recruitingHaemophilia A Without Inhibitors; Haemophilia B Without Inhibitors1562022-07-12 (+20 mo)
Liraglutide
NCT04775082
P3Active, not recruitingObesity822023-08-01
REAL 9
NCT05723835
P3Active, not recruitingSGA; Turner Syndrome472024-06-07 (-2 mo)
REAL 8
NCT05330325
P3Active, not recruitingSGA, Turner Syndrome, Noonan Syndrome, ISS4122024-08-05
REDEFINE 1
NCT05567796
P3Active, not recruitingObesity34002024-10-30 (-3 mo)
STEP Young
NCT05726227
P3Active, not recruitingObesity2122025-10-15
Explorer10
NCT05135559
P3Active, not recruitingHaemophilia A and B With and Without Inhibitors1532026-04-21 (+17 mo)
NNC0519-0130
NCT06717698
P2RecruitingChronic Kidney Disease4652026-09-01 (+13 mo)
ATHENA
NCT06200207
P3Active, not recruitingHeart Failure; Systemic Inflammation6732026-10-01 (+5 mo)
NNC0662-0419
NCT07184632
P2Active, not recruitingOverweight; Obesity2242026-12-14
UBT251
NCT07395687
P2RecruitingOverweight; Obesity3332027-01-14
ONWARDS 11
NCT07076199
P3Active, not recruitingDiabetes Mellitus, Type 18772027-01-25 (+2 mo)
ARTEMIS
NCT06118281
P3Active, not recruitingCardiovascular Risk; Acute Myocardial Infarction (AMI)100002027-01-29 (+5 mo)
CagriSema (Cagrilintide B and Semaglutide I)
NCT07011667
P3Active, not recruitingObesity6092027-03-01 (+2 mo)
RENEW 1
NCT07220642
P3Active, not recruitingObesity; Overweight3002027-05-11
RENEW 2
NCT07220759
P3Active, not recruitingOverweight; Obesity3302027-05-12
8282-Reduced
NCT06979375
P2RecruitingHeart Failure2002027-05-16
RENEW 4
NCT07745504
P3RecruitingOverweight; Obesity2852027-05-18
CagriSema
NCT07817251
P3RecruitingDiabetes Mellitus, Type 22102027-06-09
NNC0662-0419
NCT07639021
P2Active, not recruitingObesity2332027-06-14
Hibiscus 2
NCT06612268
P3RecruitingSickle Cell Disease5102027-08-27 (+20 mo)
REDEFINE 3
NCT05669755
P3Active, not recruitingCardiovascular Disease71012027-09-01 (+4 mo)
NNC0662-0419
NCT07415954
P2RecruitingDiabetes Mellitus, Type 22702027-09-03
UBT251
NCT07668388
P2RecruitingDiabetes Mellitus, Type 23002027-10-04
FOCUS
NCT03811561
P3Active, not recruitingDiabetes Mellitus, Type 215002027-11-07 (+33 mo)
8212-Preserved
NCT06979362
P2RecruitingHeart Failure2002027-11-16 (+6 mo)
OASIS 5
NCT07770841
P3RecruitingOverweight; Obesity4502028-02-22
Cagrisema
NCT07564414
P3RecruitingObesity; Type 2 Diabetes25002028-02-23
NNC6019-0001
NCT06260709
P2Active, not recruitingTransthyretin Amyloid Cardiomyopathy (ATTR CM)882028-02-29
NNC0662-3168 (Test product-A)
NCT07940803
P1/2Not yet recruitingOverweight; Obesity3002028-03-25
REDEFINE
NCT07919405
P3Not yet recruitingHypertension; Obesity14082028-06-01
AMBITION 1
NCT07931495
P3Not yet recruitingDiabetes Mellitus, Type 22002028-06-05
AMAZE 12
NCT07503210
P3Active, not recruitingObesity6062028-06-06
AMAZE 4
NCT07571109
P3RecruitingObesity; Overweight3002028-06-26
AMAZE 9
NCT07720271
P3RecruitingOverweight; Obesity9502028-06-27
FRONTIER4
NCT05685238
P3Active, not recruitingHaemophilia A; Haemophilia A With Inhibitors4512028-06-30 (+2 mo)
AMBITION 3
NCT07931573
P3Not yet recruitingType 2 Diabetes12002028-07-04
AMAZE 3
NCT07571005
P3RecruitingObesity; Overweight3002028-07-12
AMBITION4
NCT07931599
P3Not yet recruitingDiabetes Mellitus, Type 210602028-07-24
AMBITION 7
NCT07797335
P3RecruitingType 2 Diabetes; Cardiovascular Risk17782028-07-31
AMBITION 2
NCT07931547
P3Not yet recruitingType 2 Diabetes; Chronic Kidney Disease4502028-07-31
AMAZE 2
NCT07533175
P3Active, not recruitingDiabetes Mellitus; Overweight6382028-08-07
AMAZE 5
NCT07481630
P3RecruitingObesity; Knee Osteoarthritis (OA)4002028-08-14
AMAZE 6
NCT07509307
P3RecruitingObesity; Overweight4002028-08-14
Cagrilintide
NCT06780449
P3Active, not recruitingObesity4002028-08-28
AMAZE 7
NCT07668414
P3RecruitingOverweight; Obesity6502028-10-10
ZEPHYR
NCT07301034
P3RecruitingMyocardial Infarction3322028-11-14
AMAZE 8
NCT07400107
P3Active, not recruitingObesity; Overweight9852028-12-19
AMAZE 13
NCT07668401
P3Not yet recruitingObesity; Overweight4002029-01-11
AMAZE 10
NCT07822061
P3RecruitingOverweight; Obesity4002029-02-05
FRONTIERAHA
NCT07830732
P3RecruitingHaemophilia A842029-03-23
ESSENCE
NCT04822181
P3Active, not recruitingNon-alcoholic Steatohepatitis12052029-04-25 (+13 mo)
AMAZE 1
NCT07339423
P3RecruitingObesity11502029-06-26
CLEOPATTRA
NCT07207811
P3RecruitingTransthyretin Amyloid Cardiomyopathy (ATTR CM)12802029-06-29
HF-POLARIS
NCT07567001
P3RecruitingObesity; Heart Failure56102029-07-23
REIMAGINEYOUNG
NCT07282613
P3RecruitingDiabetes Mellitus, Type 2802029-09-07
Cagrilintide
NCT07253285
P3RecruitingOverweight; Obesity4602030-03-20
AMBIENCE
NCT07861100
P3Not yet recruitingCardiovascular Risk; Obesity85002030-09-16
FLORAL
NCT06609226
P3RecruitingSickle Cell Disease; Thalassemia4802030-12-30 (+13 mo)